U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H25N3O2S2.CH4O3S
Molecular Weight 487.656
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FONAZINE MESYLATE

SMILES

CS(O)(=O)=O.CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)N(C)C

InChI

InChIKey=JGKVKXPDDVRUKC-UHFFFAOYSA-N
InChI=1S/C19H25N3O2S2.CH4O3S/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5;1-5(2,3)4/h6-12,14H,13H2,1-5H3;1H3,(H,2,3,4)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including, https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf, http://www.ncbi.nlm.nih.gov/pubmed/8564192

Fonzine (also known as dimetotiazine) is an analgesics and anti-inflammatory agent marketed in Japan and Europe under the name Migristene and indicated for the treatment of migraine and headaches secondary to other disease. Fonzine exerts its activity by inhibiting serotonin and histamine H1 receptors.

CNS Activity

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Histamine H1 receptor
315
Target ID: P35367
Gene ID: 3269.0
Gene Symbol: HRH1
Target Organism: Homo sapiens (Human)
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
MIGRISTENE

Approved Use

Prophylactic and curative treatment of migraine and headaches secondary other diseases.
Primary
Approved
8429
MIGRISTENE

Approved Use

Prophylactic and curative treatment of migraine and headaches secondary other diseases.
PubMed

PubMed

TitleDatePubMed
[Clinical use of dimetotiazine (8599RP)].
1967 Dec 10
Determination of isothipendyl or dimethothiazine with their sulphoxides using third- and fourth-derivatives spectroscopy on a diode-array spectrophotometer.
1990 Jul-Aug
Patents

Patents

07951398
20

Sample Use Guides

In Vivo Use Guide
Take 20-80 mg during the first day (2-4 tablets) and then - 40 mg/day (2 tablets) up to 3 months.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
FONAZINE MESYLATE
USAN  
USAN  
Official Name English
FONAZINE MESILATE
Common Name English
10H-PHENOTHIAZINE-2-SULFONAMIDE, 10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYL-, MONOMETHANESULFONATE
Systematic Name English
10H-PHENOTHIAZINE-2-SULPHONAMIDE, 10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYL-, MONOMETHANESULPHONATE
Systematic Name English
DIMETOTIAZINE MESILATE [MART.]
Common Name English
DIMETHOTHIAZINE MESYLATE
Common Name English
PROMAQUID
Brand Name English
NEOMESTINE
Brand Name English
10-[2-(Dimethylamino)propyl]-N,N-dimethylphenothiazine-2-sulfonamide monomethanesulfonate
Systematic Name English
FONAZINE MESYLATE [USAN]
Common Name English
IL-6302 MESYLATE
Code English
CALSEKIN
Brand Name English
8599 R.P. MESILATE
Common Name English
IL-6302 MESILATE
Common Name English
Dimetotiazine mesilate [WHO-DD]
Common Name English
FONAZINE METHANESULFONATE [MI]
Common Name English
FONAZINE METHANESULFONATE
MI  
Common Name English
BONPAC
Brand Name English
BANISTYL
Brand Name English
YORISTEN
Brand Name English
MIGRISTNE
Brand Name English
DIMETOTIAZINE MESILATE
JAN   MART.   WHO-DD  
Common Name English
DIMETOTIAZINE MESILATE [JAN]
Common Name English
10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYLPHENOTHIAZINE-2-SULPHONAMIDE MONOMETHANESULPHONATE
Systematic Name English
DIMETHOTHIAZINE MESILATE
Common Name English
8599 R.P. MESYLATE
Code English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
Code System Code Type Description
SMS_ID
100000088417
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
NCI_THESAURUS
C80771
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
PUBCHEM
25715
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL346977
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID10927092
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
DRUG BANK
DBSALT002448
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
ECHA (EC/EINECS)
236-041-8
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
RXCUI
50139
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY RxNorm
CAS
7455-39-2
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
SUPERSEDED
FDA UNII
B28V86NGNK
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
MERCK INDEX
m5528
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY Merck Index
CAS
13115-40-7
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
EVMPD
SUB01755MIG
Created by admin on Fri Dec 15 17:19:12 GMT 2023 , Edited by admin on Fri Dec 15 17:19:12 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FONAZINE
SUBSTANCE RECORD
Structure of FONAZINE MESYLATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966